Please assess the completion status of the following clinical trial:

Trial Title: the Effect of Carbetocin in Decreasing Intraoperative Blood Loss in Abdominal Myomectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Patients presenting for abdominal myomectomy with documented uterine fibroids on pelvic imaging~  * Age ≥ 25 years and ≤ 50 years~ * Pre-operative hemoglobin \>10 g/dl~ * Ability to understand and the willingness to sign a written informed consent.~ * Admissible medical/surgical history~ * Five or less symptomatic uterine myomas~ * symptomatic stage 3 to 6 fibroids, according to FIGO staging~Exclusion Criteria:~* • Post-menopausal women~  * Patients with known bleeding/clotting disorders~ * Patients with a history of gynecologic malignancy~ * Hypertension.~ * Cardiac and Pulmonary diseases.~ * History of allergic reactions attributed to carbetocin

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- carbetocin (Type: EXPERIMENTAL): 100microgram in 10 cm syringe carbetocin IV just before skin incision of myomectomy.
- placebo (Type: PLACEBO_COMPARATOR): 10 cm syringe normal saline IV given just before skin incision of myomectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).